ZENSHINE PHARMA
Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on the development of small molecule drugs for cancer, viral infections, and autoimmune diseases.
ZENSHINE PHARMA
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2018-01-01
Address:
Nanjing, Jiangsu, China
Country:
China
Website Url:
http://www.cn.zenshine-pharma.com
Total Employee:
11+
Status:
Active
Contact:
86-13851624940
Email Addresses:
[email protected]
Total Funding:
28.69 M USD
Technology used in webpage:
Domain Not Resolving Euro Pound Sterling Japanese Yen Chinese Server Location
Similar Organizations
Allgenesis Biotherapeutics
Allgenesis Biotherapeutics is a clinical-stage ophthalmology company that develops small molecules and biologics for ophthalmic diseases.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
ESCAPE Bio
ESCAPE Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases.
Hainan Purple Bamboo Star Pharmaceutical Co., Ltd.
Hainan Purple Bamboo Star Pharmaceutical Co., Ltd. is a pharmaceutical company.
LucasPye BIO
A Contract Development and Manufacturing Organization (CDMO) that manufactures protein-therapeutic and viral-therapeutic drug products.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Stemcelline
Stemcelline is a biotech company developing therapeutic products based on stem cells for degenerative and autoimmune diseases.
TCR2
TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuC™ platform.
Investors List
Saizhi Bole
Saizhi Bole investment in Series C - Zenshine Pharma
Zhonghui Investment
Zhonghui Investment investment in Series C - Zenshine Pharma
Kunlun Capital
Kunlun Capital investment in Series C - Zenshine Pharma
Jumpcan
Jumpcan investment in Series C - Zenshine Pharma
Jiangbei Technology Investment Group
Jiangbei Technology Investment Group investment in Series B - Zenshine Pharma
Matrix Partners China
Matrix Partners China investment in Series B - Zenshine Pharma
Ennovation Ventures
Ennovation Ventures investment in Series B - Zenshine Pharma
Yangzi Investment Group
Yangzi Investment Group investment in Series B - Zenshine Pharma
Hankang Capital
Hankang Capital investment in Series B - Zenshine Pharma
Cybernaut Venture Capital
Cybernaut Venture Capital investment in Series B - Zenshine Pharma
Official Site Inspections
http://www.cn.zenshine-pharma.com
Unable to get host informations!!!
More informations about "Zenshine Pharma"
Company
Zenshine is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients. ... · Zenshine Pharma …See details»
Zenshine Pharma - Crunchbase Company Profile
Zenshine Pharma raised CN¥100,000,000 / Series C from Jumpcan and 3 other investors . ... Zenshine Pharma is a clinical-stage biopharmaceutical company …See details»
公司简介 - Zenshine Pharma
公司简介. 征祥医药是一家即将进入商业化阶段的创新药企业，聚焦于抗感染、抗肿瘤领域小分子创新药开发及商业化。See details»
ZENSHINE
Zenshine Pharmaceuticals Co., Ltd. was founded in 2018 by industry veterans with a track-record of successful drug discovery and development. Headquartered in Nanjing, China, Zenshine’s …See details»
Zenshine Pharmaceuticals - LinkedIn
杭州, CN Get directions 433 Airport Blvd 408 ... Ltd. (Zenshine Pharma) announced that the New Drug Application (NDA) of Seloxavir Marboxil (ZX-7101A) has been accepted by the Center for Drug ...See details»
ZENSHINE Company Profile 2024: Valuation, Funding & Investors
ZENSHINE General Information Description. Developer of drugs focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. The company is …See details»
Zenshine - Products, Competitors, Financials, Employees, …
Zenshine is a clinical-stage biopharmaceutical company that develops small-molecule therapeutics in the domains of cancer, viral infection, and inflammation. It offerings include the …See details»
Zenshine Pharmaceuticals | 领英 - 领英 (中国)
Zenshine Pharmaceuticals | 在领英上有 108 位关注者。A pharmaceutical company focusing on small molecule therapeutics in cancer, viral infection and inflammation | Zenshine is a clinical …See details»
Contact - en.zenshine-pharma.com
Email [email protected]; Phone 025-58185060; Post Code 210031; Hangzhou Branch. Hangzhou Branch of Nanjing Zenshine Pharmaceuticals Co., Ltd. Room 1503-1504 ,Building …See details»
Zenshine Pharma - Funding, Financials, Valuation & Investors
Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on small molecule drugs for cancer and autoimmune diseases. Search Crunchbase. Start Free Trial . Chrome …See details»
科学平台 - Zenshine Pharma
小分子研发平台 . 小分子药物能够与细胞内外多种靶点结合，一直是靶向疗法的支柱。和生物疗法相比，小分子药物具有明显的优势，例如成本低，口服生物利用度高，组织和肿瘤暴露量高， …See details»
News - Zenshine Pharma
Zenshine Pharma to Present the Latest Results at AACR Annual Meeting 2022 View More 2022.03.15. First patient receives ZX-101A treatment in China View More 2022.01.06. First …See details»
ZX-8177 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
新闻中心 - Zenshine Pharma
Oct 17, 2023 10月 13 日，南京征祥医药有限公司（以下简称“征祥医药”）宣布完成超亿元 c 轮融资。 本轮融资由济川药业领投，众汇投资、昆仑资本共同参与，老股东赛智伯乐继续支持。 …See details»
新一代抗流感药物！征祥医药RNA聚合酶抑制剂启动临床
Nov 2, 2021 药明康德内容团队报道. 中国药物临床试验登记与信息公示平台显示，南京征祥医药有限公司（以下简称“征祥医药”）在中国启动了一项zx-7101a片剂的1期临床研究。See details»
Science - Zenshine Pharma
The Zenshine team is working on a broad spectrum of medications to prevent and treat influenza and coronaviruses. Oncology. Cancer immunotherapies such as checkpoint inhibitors have …See details»
Xiaolin Alan Hao - Zenshine Pharma - LinkedIn
Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharma) announced that the New Drug Application (NDA) of Seloxavir Marboxil (ZX-7101A) has been… Posted by Xiaolin Alan HaoSee details»
Zenshine Pharmaceuticals' ZX-7101A Met the Primary Endpoint of …
NANJING, China, April 14, 2023 /PRNewswire/ -- On April 1 st, 2023, during the First Infection Collaboration Forum of the Chinese National Center for Infectious Diseases, Nanjing Zenshine …See details»
Zenshine Pharma to Present the Latest Results at AACR Annual …
Nanjing, March 23, 2022, Nanjing Zenshine Pharmaceuticals Co., Ltd.(Zenshine Pharma) announced that three presentations for programs ZX-101A, ZX-4081 and ZX-8177 from its …See details»